for clinical trials ( see J. Natl. Cancer Inst. 2004; 94:855 -857) . Whether the discordance between local and centralized laboratories has improved since remains open to debate.
Meanwhile, discordance between the two tests that account for almost all HER2 assessments has also raised concerns. The most common test, accounting for 80% of HER2 assessments in the United States, is the HercepTest, manufactured by Dako, in Glosgrup, Denmark. Approved concurrently with trastuzumab, the HercepTest is based on immunohistochemical (IHC) methods -clinicians using it evaluate staining reactions between HER2 proteins and an antibody on slides of breast tissue. A positive fi nding is contingent on staining intensity, which ranges from 0 (negative) to 1+ (weakly positive) to 2+ (moderately positive) and fi nally to 3+ (strongly positive).
The second test relies on fl uorescence in situ hybridization (FISH). Unlike IHC, which checks for overexpressed HER2 protein, FISH checks for excessive HER2 DNA. Normal cells each have two copies of the HER2 gene on chromosome 17 -one inherited from the mother and one from the father. In HER2-positive cancer cells, the gene is amplifi ed -each cell has more than two copies. Perez, who was on the ASCO -CAP guideline committee, said she's contacted several times a week by pathologists who don't understand how to interpret the newer threshold. The problem, she said, is that the FISH manufacturer's package inserts and the guidelines both still state that a FISH ratio of 2.0 warrants trastuzumab treatment. But clinicians are aware of the ASCO -CAP 2.2 cutoff and do not realize scores between 2.0 and 2.2 also fall in the trastuzumab treatment range.
According to the 2007 guidelines, equivocal fi ndings on both FISH and IHC justify trastuzumab treatment. But Press said that clinicians who aren't aware of this technicality might base treatment decisions on the higher ASCO -CAP cutoffs instead of what the package inserts call for. And that's a concern because up to 3,000 women fall between FISH ratios of 2.0 and 2.2. The newer IHC cutoff isn't as problematic, he added, because 3+ fi ndings, defi ned as 3+ staining on between 10% and 30% of a given sample, will almost invariably cover at least 30% of a breast tissue slide.
Press, Perez, and other experts interviewed for this article agreed that the new thresholds can be challenging to interpret and that pathologists should base treatment decisions on earlier thresholds -particularly FISH ratios of 2.0 or greater -linked to trastuzumab benefi ts in clinical data. "If the FISH is done properly, a ratio of greater than 2.0 is, by defi nition, amplifi cation," said John Glaspy, M.D., an oncologist at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center. Asked about reimbursement worries when pathologists rely on test manufacturers ' less stringent criteria, Glaspy answered that they had never had problems getting Herceptin or lapatinib (indicated for HER2-positive patients with metastatic disease) covered in patients with ratios at the old threshold. Hammond concurred: "A fi nding of 2.0 does not interfere with trastuzumab reimbursement," she said.
Still, should clinical laboratories eschew the guidelines, they might jeopardize their CAP accreditation, Press warned. "I have a clinical lab that is routinely inspected by CAP," he said. "And CAP mandates that if we don't follow the guidelines, the lab can be given a defi ciency (or a citation for departing from recommended procedures). And that puts me in a bind because a whole body of accumulated clinical data supports the 2.0 ratio cutoff." To that, Hammond responded, "These measurement artifacts would have no bearing on laboratory inspection criteria. It's not a clinically relevant problem that would lead to a loss of accreditation.
IHC versus FISH
Meanwhile, clinicians still disagree over whether FISH or IHC is the better test; both have their pros and cons. Pathologists have more experience with IHC, which also has a lower cost -roughly $150, compared with $300 for FISH. But IHC also relies on subjective interpretations; those who run the tests must qualify shades of brown stain, and observers can reach different conclusions. Moreover, sample results can be infl uenced by the time to and duration of fi xation. FISH, however, generates quantitative ratios that Press, for one, prefers, but its results can also be infl uenced by fi xatives, chemicals, or heat.
At fi rst, the two tests suffered from poor concordance -their results didn't always match up. But now that's a lesser problem. In a recent editorial appearing in Negative results with either FISH or IHC should be treated cautiously, Perez said. According to her data, 8% of breast cancer tumors deemed to be FISH negative turned out to be IHC positive when retested or evaluated by a different laboratory. "So in the case of negative results, it's advisable to repeat the test you started with or to run a different test," she said.
FISH Ratio Outmoded?
In yet another discovery from the same study, Perez found that centromere copy numbers used to calculate FISH ratios are unnecessary, particularly when HER2 copy numbers are high. FISH manufacturer guidelines base positivity on the ratio, which is also what most pathologists also rely on. But even before trastuzumab came on the market in 1998, the FDA had approved a HER2 FISH test based only on copy number. According to that test, known as the INFORM assay and manufactured by Ventana Medical Systems in Tucson, Ariz., positive results were based on 4.0 HER2 copy numbers per cell. The 2007 ASCO -CAP guidelines acknowledge this approach as valid (in addition to the ratio), but they raise the threshold from 4.0 to 6.0 HER2 copy numbers per cell. 
